TY - JOUR
T1 - Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
AU - Qin, Kang
AU - Wang, Kaiwen
AU - Li, Shenduo
AU - Hong, Lingzhi
AU - Padmakumar, Priyadharshini
AU - Waree, Rinsurongkawong
AU - Hubert, Shawna M.
AU - Le, Xiuning
AU - Vokes, Natalie
AU - Rai, Kunal
AU - Vaporciyan, Ara
AU - Gibbons, Don L.
AU - Heymach, John V.
AU - Lee, J. Jack
AU - Woodman, Scott E.
AU - Chung, Caroline
AU - Jaffray, David A.
AU - Altan, Mehmet
AU - Lou, Yanyan
AU - Zhang, Jianjun
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/3
Y1 - 2024/3
N2 - Docetaxel +/− ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/− ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/− ramucirumab (Formula presented.) ; platinum/taxane-based regimens (Formula presented.)). Progression-free survival (PFS) and overall survival (OS) were compared among different subpopulations with different cancer gene mutations and between patients who received docetaxel +/− ramucirumab versus platinum/taxane-based regimens. Among patients who received docetaxel +/− ramucirumab, the top mutated cancer genes included TP53 (Formula presented.), KRAS (Formula presented.), EGFR (Formula presented.), STK11 (Formula presented.), ERBB2 (HER2) (Formula presented.), etc. None of these cancer gene mutations or PD-L1 expression was associated with PFS or OS. Platinum/taxane-based regimens were associated with a significantly longer mQS (13.00 m, 95% Cl: 11.20–14.80 m versus 8.40 m, 95% Cl: 7.12–9.68 m, LogRank (Formula presented.)) than docetaxel +/− ramcirumab. Key prognostic factors including age, histology, and performance status were not different between these two groups. In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/− ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/− ramucirumab in this patient population.
AB - Docetaxel +/− ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/− ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/− ramucirumab (Formula presented.) ; platinum/taxane-based regimens (Formula presented.)). Progression-free survival (PFS) and overall survival (OS) were compared among different subpopulations with different cancer gene mutations and between patients who received docetaxel +/− ramucirumab versus platinum/taxane-based regimens. Among patients who received docetaxel +/− ramucirumab, the top mutated cancer genes included TP53 (Formula presented.), KRAS (Formula presented.), EGFR (Formula presented.), STK11 (Formula presented.), ERBB2 (HER2) (Formula presented.), etc. None of these cancer gene mutations or PD-L1 expression was associated with PFS or OS. Platinum/taxane-based regimens were associated with a significantly longer mQS (13.00 m, 95% Cl: 11.20–14.80 m versus 8.40 m, 95% Cl: 7.12–9.68 m, LogRank (Formula presented.)) than docetaxel +/− ramcirumab. Key prognostic factors including age, histology, and performance status were not different between these two groups. In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/− ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/− ramucirumab in this patient population.
KW - docetaxel with or without ramucirumab
KW - metastatic non-small-cell lung cancer
KW - platinum–taxane
UR - http://www.scopus.com/inward/record.url?scp=85187674009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85187674009&partnerID=8YFLogxK
U2 - 10.3390/cancers16050935
DO - 10.3390/cancers16050935
M3 - Article
C2 - 38473297
AN - SCOPUS:85187674009
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 5
M1 - 935
ER -